You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

401 Results
Document
Mar 2020
 
Document
Sep 2020
Guidelines and Advice
Status: Current
Apr 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    procarbazine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab (Unfunded),
methotrexate,
procarbazine,
cytarabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2020
Statistical Reports
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trastuzumab,
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023
Document
Jan 2021
Document
Apr 2021

Pages